Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH (Reuters) - Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news